Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer

Chong, Ari; Song, Hee Jo; Min, Jung Joon; Jeong, Shin Young; Ha, Jung Min; Kim, Jahae; Yoo, Su Ung; Oh, Jong Ryool; Bom, Hee Seung

doi:10.1007/s13139-010-0051-y

Cited by 29 publications

(31 citation statements)

References 14 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, Salvatori et al stated that "perfect timing" probably does not exist because of differences in 131 I kinetics in different patients and in different metastases (26). A delay of 7 d for this study was chosen to allow washout of background activity (27). Similar to 131 I, 124 I uptake differs significantly among metastases, although peak uptake is generally observed about 24 h after administration (28,29).…”

Section: Discussionmentioning

confidence: 99%

Quantitative Comparison of ¹²⁴I PET/CT and ¹³¹I SPECT/CT Detectability

et al. 2015

View full text Add to dashboard Cite

Radioiodine therapy with 131 I is used for treatment of suspected recurrence of differentiated thyroid carcinoma. Pretherapeutic 124 I PET/CT with a low activity (∼1% of 131 I activity) can be performed to determine whether uptake of 131 I, and thereby the desired therapeutic effect, may be expected. However, false-negative 124 I PET/CT results as compared with posttherapeutic 131 I SPECT/CT have been reported by several groups. The purpose of this study was to investigate whether the reported discrepancies may be ascribed to a difference in lesion detectability between 124 I PET/CT and 131 I SPECT/CT and, hence, whether the administered 124 I activity is sufficient to achieve equal detectability. Methods: Phantom measurements were performed using the National Electrical Manufacturers Association 2007 image-quality phantom. As a measure of detectability, the contrast-to-noise ratio was calculated. The 124 I activity was expressed as the percentage of 131 I activity required to achieve the same contrast-to-noise ratio. This metric was defined as the detectability equivalence percentage (DEP). Results: Because lower DEPs were obtained for smaller spheres, a relatively low 124 I activity was sufficient to achieve similar lesion detectability between 124 I PET/CT and 131 I SPECT/CT. DEP was 1.5%, 1.9%, 1.9%, 4.4%, 9.0%, and 16.2% for spheres with diameters of 10, 13, 17, 18, 25, and 37 mm, respectively, for attenuation-and scatter-corrected SPECT versus point-spread function (PSF) model-based and time-of-flight (TOF) PET. For no-PSF no-TOF PET, DEP was 3.6%, 2.1%, 3.5%, 7.8%, 15.1%, and 23.3%, respectively. Conclusion: A relatively low 124 I activity of 74 MBq (∼1% of 131 I activity) is sufficient to achieve similar lesion detectability between 124 I PSF TOF PET/CT and 131 I SPECT/CT for small spheres (#10 mm), since the reported DEPs are close to 1%. False-negative 124 I PET/CT results as compared with posttherapeutic 131 I SPECT/CT may be ascribed to differences in detectability for large lesions (.10 mm) and for no-PSF no-TOF PET, since DEPs are greater than 1%. On the basis of DEPs of 3.5% for lesion diameters of up to 17 mm on no-PSF no-TOF PET, 124 I activities as high as 170 MBq may be warranted to obtain equal detectability.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantitative Comparison of ¹²⁴I PET/CT and ¹³¹I SPECT/CT Detectability

et al. 2015

View full text Add to dashboard Cite

show abstract

“…They reported that the seventh day scan is more sensitive than third day scan. Chong et al reported that 22% of lung metastasis and 33% of bone metastases that were not shown on the third day scan, though they were detected on the seventh day scan (Chong et al, 2010) (Figure 10). Focal uptake in the anterior neck was supposed to be usual remnant thyroid tissue.…”

Section: Diagnostic Value Of Rxwbsmentioning

confidence: 98%

“…However, current guidelines for I-131 therapy differ in their recommendations for the optimal time of the RxWBS ranging from 48 -72 hours (Becker et al, 1996;Luster et al, 2008) to 2 -10 days (Cooper et al, 2009). Also, there is a lot of discrepancy in the published literature regarding the optimal timing of RxWBS (Cholewinski et al, 2000;Chong et al, 2010;Durante et al, 2006;Hindie et al, 2003;Hung et al, 2009;Khan et al, 1994;Nemec et al, 1979). So far, several studies were done for evaluating efficacy or accuracy of RxWBS which was done at different timing after high-dose I-131 therapy.…”

Section: Imaging Timing Of Rxwbsmentioning

confidence: 99%

“…The ratio of early washout was different between remnants and metastatic lesions. Chong et al conducted RxWBS on the third and seventh days after I-131 therapy in 60 cases from 52 patients with lung or bone metastases of thyroid cancer (Chong et al, 2010). They showed that 22% of lung metastases and 33% of bone metastases that were not shown on the third day scan were detected on the seventh day scan (Figure 4 and 5).…”

Section: Imaging Timing Of Rxwbsmentioning

confidence: 99%

See 1 more Smart Citation

Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer

Song¹,

Chong²

2011

12 Chapters on Nuclear Medicine

Self Cite

View full text Add to dashboard Cite

“…Diagnostic 131 I whole-body scintigraphy (DWS) can be used to acquire information on the presence of iodine-avid remnant thyroid tissue and also to detect locoregional or distant metastases [19]. Post-ablation 131 I whole-body scintigraphy (TWS) is also useful in this context, particularly in patients with elevated serum thyroglobulin levels, because TWS is more sensitive than DWS when used to detect metastatic disease [4,20]. Our clinical experience has taught us that some patients exhibit 131 I retention in the salivary glands on either DWS or TWS.…”

Section: Introductionmentioning

confidence: 99%

Significance of Salivary Gland Radioiodine Retention on Post-ablation 131I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma

Lee

et al. 2014

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose We investigated whether 131 I whole-body scintigraphy could predict functional changes in salivary glands after radioiodine therapy. Methods We evaluated 90 patients who received initial highdose (≥3.7 GBq) radioiodine therapy after total thyroidectomy. All patients underwent diagnostic (DWS) and postablation (TWS) 131 I whole-body scintigraphy. Visual assessment of salivary radioiodine retention on DWS and TWS was used to divide the patients into two types of groups: a DWS+ or DWS-group and a TWS+ or TWS-group. Salivary gland scintigraphy was also performed before DWS and at the first follow-up visit. Peak uptake and %washout were calculated in ROIs of each gland. Functional changes (Δuptake or Δwashout) of salivary glands after radioiodine therapy were compared between the two groups. Results Both peak uptake and the %washout of the parotid glands were significantly lower after radioiodine therapy (all p values <0.001), whereas only the %washout were significantly reduced in the submandibular glands (all p values <0.05). For the parotid glands, the TWS+ group showed larger Δuptake and Δwashout after radioiodine therapy than did the TWS-group (all p values <0.01). In contrast, the Δuptake and Δwashout of the submandibular glands did not significantly differ between the TWS+ and TWS-groups (all p values >0.05). Likewise, no differences in Δuptake or Δwashout were apparent between the DWS+ and DWS-groups in either the parotid or submandibular glands (all p values >0.05). Conclusion Salivary gland radioiodine retention on postablation 131 I scintigraphy is a good predictor of functional impairment of the parotid glands after high-dose radioiodine therapy.

show abstract

Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer

Abstract: 7DWBS showed more lung or bone metastatic lesions than 3DWBS. After high-dose I-131 therapy, 7DWBS should be considered regardless of the results of the 3DWBS for the diagnosis of lung or bone metastasis from well-differentiated thyroid cancer.

Cited by 29 publications

References 14 publications

Quantitative Comparison of ¹²⁴I PET/CT and ¹³¹I SPECT/CT Detectability

Quantitative Comparison of ¹²⁴I PET/CT and ¹³¹I SPECT/CT Detectability

Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer

Significance of Salivary Gland Radioiodine Retention on Post-ablation 131I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma

Contact Info

Product

Resources

About

Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer

Abstract: 7DWBS showed more lung or bone metastatic lesions than 3DWBS. After high-dose I-131 therapy, 7DWBS should be considered regardless of the results of the 3DWBS for the diagnosis of lung or bone metastasis from well-differentiated thyroid cancer.

Cited by 29 publications

References 14 publications

Quantitative Comparison of 124I PET/CT and 131I SPECT/CT Detectability

Quantitative Comparison of 124I PET/CT and 131I SPECT/CT Detectability

Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer

Significance of Salivary Gland Radioiodine Retention on Post-ablation 131I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma

Contact Info

Product

Resources

About

Quantitative Comparison of ¹²⁴I PET/CT and ¹³¹I SPECT/CT Detectability

Quantitative Comparison of ¹²⁴I PET/CT and ¹³¹I SPECT/CT Detectability